Goldline Pharmaceutical Limited officially opened its SME IPO for public subscription on May 12, 2026, marking another active entry in India’s growing SME IPO market. The pharmaceutical marketing company is seeking to raise approximately ₹11.61 crore through a completely fresh issue of shares, with no offer-for-sale component included in the issue.
The IPO price band has been fixed at ₹41 to ₹43 per equity share, while the issue will remain open for subscription until May 14. The shares are proposed to be listed on the BSE SME platform, with the tentative listing scheduled for May 19, 2026. Market analysts noted that investor interest remained strong during the opening session due to the company’s improving financial performance and growing pharmaceutical distribution network.
Goldline Pharmaceutical, headquartered in Nagpur, operates as a pharmaceutical marketing and distribution company with business presence across multiple Indian states including Maharashtra, Madhya Pradesh, Goa, Bihar, Rajasthan, Odisha, Tamil Nadu, and Chhattisgarh. The company markets a wide portfolio of pharmaceutical formulations and healthcare products through third-party manufacturing partnerships.
According to recent financial disclosures, the company reported strong revenue growth over the last two financial years. Revenue increased from around ₹19.85 crore in FY2023 to more than ₹28 crore in FY2025, while profit after tax rose significantly to approximately ₹2.83 crore. Industry observers believe the company’s improving margins and expanding regional reach have helped generate positive sentiment around the IPO.
The grey market premium (GMP) for the IPO has also attracted attention in the market. Reports indicate that the GMP surged ahead of the issue opening, signaling expectations of healthy listing gains despite broader market volatility. Analysts noted that strong SME investor participation and limited issue size could continue to support demand during the subscription period.
The company plans to utilize the IPO proceeds primarily for repayment of borrowings, strengthening working capital requirements, and supporting general corporate purposes. As of March 2026, Goldline Pharmaceutical reportedly carried borrowings of more than ₹9 crore, and debt reduction remains one of the key objectives of the public offering.
Market experts have also pointed out certain risks associated with the business, including dependence on third-party manufacturers, concentration in specific regional markets, and competitive pressure within India’s pharmaceutical marketing segment. However, the company’s rising profitability, expanding operating regions, and growing investor interest have positioned the IPO among the closely watched SME offerings this week.